Deficiency of the antidiuretic hormone arginine vasopressin (AVP) underlies diabetes insipidus, which is characterized by the excretion of abnormally large volumes of dilute urine and persistent thirst. In this issue of the JCI, Shi et al. report that Sel1L-Hrd1 ERassociated degradation (ERAD) is responsible for the clearance of misfolded pro-arginine vasopressin (proAVP) in the ER. Additionally, mice with Sel1L deficiency, either globally or specifically within AVP-expressing neurons, developed central diabetes insipidus. The results of this study demonstrate a role for ERAD in neuroendocrine cells and serve as a clinical example of the effect of misfolded ER proteins retrotranslocated through the membrane into the cytosol, where they are polyubiquitinated, extracted from the ER membrane, and degraded by the proteasome. Moreover, proAVP misfolding in hereditary central diabetes insipidus likely shares common physiopathological mechanisms with proinsulin misfolding in hereditary diabetes mellitus of youth.
In high demand: proAVP is prone to misfolding Arginine vasopressin (AVP) is an antidiuretic hormone that is synthesized as part of a larger hormone precursor (1) . The AVP gene is located on the short arm of chromosome 20 (20p13), and the three exons of AVP encode the four main segments of the prepro-hormone: a 19-amino acid signal peptide that directs the nascent protein to the ER, the AVP nonapeptide moiety, the 93-amino acid neurophysin II (NPII) moiety, and a C-terminal 39amino acid glycopeptide called copeptin. Upon cotranslational translocation into the ER lumen, the signal sequence is cleaved, and the prohormone undergoes N-linked glycosylation.
Folding of NP ( Figure 1A ) is challenging, because the protein consists of two β-sheet domains, with amino acid residues 11-37 and 59-82 forming two 4-stranded antiparallel β-sheets connected by a threeturn helix (residues 39-49) and a nineresidue (residues 50-58) loop that defines the back of the AVP-binding pocket (2) . There are eight disulphide bridges, and the NP-AVP dimer is formed by the interaction of two β-sheet domains ( Figure 1A ). After folding and formation of the eight disulfide bonds, the prohormone exits the ER, passes through the Golgi apparatus, and is sorted into neurosecretory granules, where processing by prohormone convertases separates the AVP, NPII, and copeptin moieties. The secretory granules reach nerve endings where AVP, NPII, and copeptin are secreted into the circulation by regulated exocytosis. Thirst and AVP release are regulated not only by classical homeostatic, interosensory feedback (plasma osmolality, volume, and pres-sure), but also by novel exterosensory, anticipatory signals (3).
AVP-producing cells are highly secretory, as AVP in the circulation is synthesized by only a few (approximately 10,000 in the rat and 100,000 in humans) large magnocellular neurons, whose cell bodies are located in the supraoptic and paraventricular nuclei of the hypothalamus. Each magnocellular neuron has one axon that projects to the posterior pituitary, where it gives rise to 10,000 neurosecretory endings that are packed with large dense-core vesicles (LDCVs) containing the products of AVP, AVP, NPII, and copeptin. The rat hypothalamus contains 100 ng AVP, or 6 × 10 13 molecules (AVP has a relative molecular mass of approximately 1,000 g/mol). As a single LDCV contains 1 × 10 4 molecules of AVP, the hypothalamic AVP content is equivalent to 6 × 10 9 LDCVs (4). The high level of proAVP generated in AVP-producing cells needs to be correctly folded, and any misfolded WT and/or mutant proAVP needs to be destroyed.
AVP, ERAD, and autosomal dominant central diabetes insipidus
Autosomal dominant central diabetes insipidus is secondary to AVP mutations that result in misfolding and aggregation of the protein in the ER (1). ER-associated degradation (ERAD) is a principal quality control mechanism in cells responsible for targeting misfolded ER proteins for cytosolic degradation (5) . More than 70 human diseases, including hereditary central and nephrogenic diabetes insipidus, have been linked to ERAD dysfunction (6) . In mammals, the most well-characterized ERAD machinery is the highly conserved complex of suppressor-enhancer of lin-12-like and hydroxymethylglutaryl-CoA reductase degradation protein 1 (SEL1L-HRD1), which consists of the E3 ubiquitin ligase HRD1 and its adaptor protein SEL1Lc ( Figure 1B ). In this issue Shi et al. October 2017 (7) report that mice with induced Sel1L deficiency, either globally or only within AVP-expressing neurons, develop central diabetes insipidus, with no magnocellular neuronal death or loss, as has been previously observed (8) . These mice are polyuro-polydipsic, with low circulating AVP levels and increased urine osmolality after desmopressin (dDAVP) administration. The Sel1L-deficient experimental model of central diabetes insipidus is unlikely to be observed in humans, as Sel1L loss is embryonically lethal (9) . Three-week-old mice with Sel1L deficiency specifically in AVP neurons (Sel1L AVP mice) lacked AVP-positive transport vesicles in axons, a phenotype that explains the development of the central diabetes insipidus phenotype in these mice. Using the CRISPR/Cas9 system, Shi et al. (7) generated SEL1L-and HRD1deficient human HEK293T cells and murine neuroblastoma Neuro2A (N2a) cells. N2a cells have been regularly used to express AVP mutants responsible for hereditary autosomal dominant central diabetes insipidus in humans (10) . Both WT and some human proAVP mutants were shown to be substrates of Sel1L-Hrd1 ERAD. In Sel1L-null N2a cells, both WT and mutant proAVP appeared to accumulate in amyloid-like fibrillar structures, similar to what has been previously observed for human AVP mutants (10) . Together, these results demonstrate that Sel1L-Hrd1 ERAD helps to limit ER retention and aggregation of WT proAVP.
Shi et al. (7) further characterized WT proAVP and a human proAVP mutant that The conformational maturation of the AVP precursor proAVP within the ER requires ERAD activity of the SEL1L-HRD1 protein complex. Misfolded proAVP is recruited to the ERAD complex via the activity of various ER chaperones such as binding Ig protein (BiP), ER degradation-enhancing α-mannosidase-like protein (EDEM), osteosarcoma amplified 9 (OS9), and XTP3-transactivated gene B protein (XTP3B) for cytosolic degradation. SEL1L-HRD1 is part of an E3 ligase-coupled dislocation complex that integrates the coupled processes of substrate ubiquitination (Ub), membrane extraction via VCP/p97, and proteolytic destruction by the 26S proteasome (5, 13) .
